Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

Oral Oncology

Volumn 45, Issue 7, 2009, Pages 574-578

  Locati, L D ^a   Bossi, P ^a   Perrone, F ^a   Potepan, P ^a   Crippa, F ^a   Mariani, L ^a   Casieri, P ^a   Orsenigo, M ^a   Losa, M ^a   Bergamini, C ^a   Liberatoscioli, C ^a   Quattrone, P ^a   Calderone, R G ^a   Rinaldi, G ^a   Pilotti, S ^a   Licitra, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cetuximab; Head and neck squamous cell carcinoma; Metastatic disease; Palliative treatment; Salivary gland cancer; Target therapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ERUPTION; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HAIR DISEASE; HAIR LOSS; HUMAN; HUMAN TISSUE; HYPERTRICHOSIS; IMMUNOHISTOCHEMISTRY; KERATITIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH LESION; NAIL; NEVUS; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RECURRENT CANCER; RHAGADES; SALIVARY GLAND CARCINOMA; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; TRICHOMEGALIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS; YOUNG ADULT;

EID: 67449087686     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.07.010     Document Type: Article

References (21)

1. Spiro R.H. Management of malignant tumors of the salivary glands. Oncology (Williston Park) 12 (1998) 671-680
2. Laurie S.A., and Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24 (2006) 2673-2678
3. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M. Treatment relevant immunophenotyping of 139 salivary gland carcinomas (SGCs). AACR-NCI-EORTC, Meeting proceedings, 2005, abs C252, 263.
4. Gibbons M.D., Manne U., Carroll W.R., Peters G.E., Weiss H.L., and Grizzle W.E. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111 (2001) 1373-1378
5. Mori M., Naito R., Tsukitani K., Okada Y., Hayashi T., and Kato K. Immunohistochemical distribution of human epidermal growth factor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol 411 (1987) 499-507
6. Fan C.Y., Melhem M.F., Hosal A.S., Grandis J.R., and Barnes E.L. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 127 (2001) 1075-1079
7. Yamada K., Iwai K., Okada Y., and Mori M. Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol 415 (1989) 523-531
8. Vered M., Braunstein E., and Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24 (2002) 632-636
9. Vermorken J.B., Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25 (2007) 2171-2177
10. Vermorken J, Mesia R, Vega V, Remenar E, Hitt R, Kawecki A, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - Results of a randomized phase III (Extreme) study. J Clin Oncol ASCO annual meeting proceedings, vol. 25, 2007. p. 18S.
11. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
12. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
14. Perrone F., Suardi S., Pastore E., Casieri P., Orsenigo M., Caramuta S., et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 12 (2006) 6643-6651
15. Kaplan E.L., and Meyer P. Non parametric estimation for incomplete observations. J Am Stat Assoc 53 (1958) 457-474
16. Bossi P., Liberatoscioli C., Bergamini C., Locati L., Fava S., Rinaldi G., et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 18 (2007) 601-602
17. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M. Phase II trial of gefitinib in patients with incurable salivary gland cancer. ASCO annual meeting proceedings, vol. 23, 2005. p. 508s.
18. Agulnik M., Cohen E.W., Cohen R.B., Chen E.X., Vokes E.E., Hotte S.J., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25 (2007) 3978-3984
19. Umeda M., Nishimatsu N., Masago H., Ishida Y., Yokoo S., Fujioka M., et al. Tumor-doubling time and onset of pulmonary metastasis from adenoid cystic carcinoma of the salivary gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88 (1999) 473-478
20. Faivre S., Raymond E., Casiraghi O., Temam S., and Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23 (2005) 6271-6273
21. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di N.F., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286